source
- Lilly's obesity drug shows strong weight loss but fails to demonstrate cardiovascular benefit in heart disease trialEli Lilly released Phase 3 results for its next‑generation obesity therapy retatrutide, showing it produces substantial weight loss in a trial of nearly 2,000 participants with severe obesity and e…
- Repligen to acquire BioLife Solutions for $1.5 billion as BeOne announces $300 million US expansionRepligen announced it will acquire cell‑processing services provider BioLife Solutions in a transaction valued at roughly $1.5 billion. The deal adds BioLife’s platform to Repligen’s portfolio of b…